This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
Henry Schein (HSIC) Buys TriMed to Expand in Orthopedic Space
by Zacks Equity Research
According to Henry Schein (HSIC), the upper and lower extremities are among the fastest-growing segments of orthopedics, representing a total addressable market of more than $5.5 billion.
3 Soaring, Highly-Ranked Value Stocks to Buy in April
by Benjamin Rains
3 highly-ranked Zacks stocks that offer an attractive combination of impressive valuations, soaring stock prices, and long-term upside in crucial, non-flashy industries.
GE HealthCare's (GEHC) New Launch to Enhance Cardiac Care
by Zacks Equity Research
GE HealthCare's (GEHC) latest offering is likely to expand access to cardiac care by enabling more medical professionals to be able to capture cardiac images.
Glaukos' (GKOS) iDose TR Receives Permanent J- Code From CMS
by Zacks Equity Research
Glaukos (GKOS) announces the receipt of a permanent J-code for iDose TR from the CMS, which is likely to boost the billing and payment process.
Reasons to Add Cardinal Health (CAH) to Your Portfolio Now
by Zacks Equity Research
Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.
Here's Why You Should Add Ecolab (ECL) to Your Portfolio Now
by Zacks Equity Research
Ecolab's (ECL) focus on research and development raises optimism about the stock.
Globus Medical (GMED) Gains From New Launches Amid Macro Issues
by Zacks Equity Research
Globus Medical (GMED) witnesses notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.
Align (ALGN) Debuts Invisalign Palatal Expander in New Markets
by Zacks Equity Research
Align's (ALGN) Invisalign Palatal Expander system is now available in Australia and New Zealand for skeletal and dental expansion in growing patients.
Veeva Systems (VEEV) Makes Change to Front Office (revised)
by Zacks Equity Research
Veeva Systems' (VEEV) CFO Brent Bowman steps down, leading analysts to weigh in on the impact and prospects for the cloud-solutions company.
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now
by Zacks Equity Research
PacBio's (PACB) strong product demand and top-line growth raise optimism about the stock.
QuidelOrtho's (QDEL) QuickVue Gets FDA Nod for COVID Testing
by Zacks Equity Research
QuidelOrtho (QDEL) announces the FDA's approval of QuickVue, which is likely to be used for convenient and accurate COVID-19 pathogen testing.
Exact Sciences' (EXAS) Oncoguard Esophagus Test Looks Promising
by Zacks Equity Research
Exact Sciences (EXAS) advances the development of the non-endoscopic Oncoguard Esophagus test to screen for esophageal cancer and pre-cancer.
Here's Why Investors Should Buy Alcon (ALC) Stock Right Now
by Zacks Equity Research
Strength in the Surgical and Vision Care businesses bodes well for Alcon (ALC).
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
Veeva Systems' (VEEV) CFO Resignation Sparks 6% Stock Drop
by Zacks Equity Research
Veeva Systems' (VEEV) CFO, Brent Bowman, steps down, causing a 6% stock price decline. Analysts weigh in on the impact and prospects for the cloud-solutions company.
Baxter's (BAX) Latest FDA Approval to Boost Infusion Therapy
by Zacks Equity Research
Baxter's (BAX) Novum IQ Infusion Platform is likely to help enhance patient safety and efficiency for clinicians following the FDA's clearance.
Three Reasons to Retain Avanos (AVNS) Stock in Your Portfolio
by Zacks Equity Research
Avanos' (AVNS) strong product line and focus on R&D raise optimism about the stock.
AngioDynamics (ANGO) Settles Patent Litigations With BD
by Zacks Equity Research
AngioDynamics (ANGO) announces its settlement agreement with BD's affiliate, C.R. Bard, to resolve a 10-year dispute over outstanding patent litigation.
Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
Here's Why DaVita HealthCare (DVA) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Prestige Consumer (PBH) Banks on its Portfolio Amid Cost Woes
by Zacks Equity Research
Prestige Consumer (PBH) develops long-term partnerships across its diverse retail footprint and invests heavily in the e-commerce channel.
Thermo Fisher (TMO) Debuts a New In-Line Metrology Solution
by Zacks Equity Research
Thermo Fisher's (TMO) new LInspector Edge In-line Mass Profilometer delivers real-time, full-coverage mass loading analysis for battery electrode coating.
Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now
by Zacks Equity Research
The strength of the CAG Diagnostics business buoys optimism for IDEXX (IDXX).
Three Reasons to Retain Revvity (RVTY) Stock in Your Portfolio
by Zacks Equity Research
Revvity's (RVTY) strong product portfolio raises optimism about the stock.
OPKO Health (OPK) to Restructure After Asset Buyout by Labcorp
by Zacks Equity Research
OPKO Health (OPK) expects to re-establish profitability in its clinical laboratory business via its latest efforts to streamline its laboratory services business.